Bioproduction is the production of industrially or medically important products by using natural or recombinant cells or living systems such as bacteria, virus, yeast, animal cells, plant cells or transgenics. The end products d ....see more
The global biologics safety testing market is projected to reach USD 9.66 billion by 2031, growing at a CAGR of 11.6% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
The global 3D bioprinting market, valued at US$1.2 billion in 2023, stood at US$1.3 billion in 2024 and is projected to advance at a resilient CAGR of 12.7% from 2024 to 2029, culminating in a forecasted valuation of US$2.4 billion by the end of the period. The market growth is fueled by the growing adoption of 3D bioprinting technology in the pharmaceutical and cosmetic industries, technological advancements in 3D bioprinting, and the rising demand for organ transplants.
The global pyrogen testing market growth is primed to transition from $927 million in 2020 to $1,689 million by 2025, showcasing a strong CAGR of 12.7%. Market drivers include increasing demand for personalized medicine, R&D in pharmaceuticals and biotechnology, rising chronic and infectious diseases, and growing awareness of food safety.
The global high throughput process development market is expected to reach USD 415.5 Million in 2021 from USD 212.1 Million in 2016, at a CAGR of 14.4% from 2016 to 2021. Major players operating in the high throughput process development market include Danaher (US), GE Healthcare (US), Agilent Technologies (US), Merck Millipore (Germany), and Thermo Fisher Scientific (US).
The global downstream processing market is projected to grow at a CAGR of 16.4%. In this report, the global downstream processing market is broadly segmented on the basis of technique, product, application, end user, and region.